Introduction
Despite advances in understanding the pathophysiology of T2DM and consequent development of plethora of new anti-diabetic medications, drugs targeting β-cell function and/or mass are still wanting. Intensive insulin therapy (IIT) [1] , thiazolidinedione [2] , dipeptidyl peptidase4 inhibitors (DPP4i) [3] and glucagon-like peptide1 (GLP-1) agonists [4] have exhibited glycemic durability, if used in early stages of disease. IIT is usually not accepted by the patients at diagnosis of diabetes, and is associated with weight gain and hypoglycemia, whereas weight gain, increased risk of heart failure and atypical fractures are accompanied with use of thiazolidinedione. DPP4i and GLP1 agonists fail to sustain glycemic durability with increasing duration of disease and are associated with gastrointestinal intolerance, pancreatitis and C-cell hyperplasia [5] .
β-cell failure is progressive and inexorable with advancing duration of diabetes.
Therefore, targeting β-cells through pancreatic/islet transplantation and novel β-cells regenerative therapies like stem cells seems to be a pragmatic approach [6, 7] .
Limitations of pancreatic/islet transplantation include restricted availability of cadaveric pancreata, progressive decline in insulin independence, graft rejection and immunosuppression-associated complications [8] . Therefore, interest is growing in stem cells that possess homing-in, differentiation and transdifferentiation properties.
Bone marrow is enriched with mononuclear cells (MNCs), hematopoietic stem cells (HSCs) and a few mesenchymal stem cells (MSCs) [9, 10] . Several studies have demonstrated that use of bone marrow derived-MNCs transplantation in patients with T2DM resulted in significant decrease in insulin requirement, though C-peptide response was variable [11, 12] . MSCs are multipotent stem cells that have ability to differentiate into variety of cell types, thereby making these cells an attractive therapeutic tool for cell transplantation. Jiang et al. studied the efficacy of placentaderived MSCs (PD-MSCs) in patients with long-standing T2DM and showed a significant increase in C-peptide by 40% with achievement of ≥50% reduction in insulin requirement. However, the heterogeneity in glycemic control at inclusion, lack of a placebo arm and short follow-up were limitation of this study [13] . Recently, a study demonstrated the dose-response relationship of allogenic bone marrow-derived mesenchymal precursor cells in patients with T2DM. The higher the dose of MSCs, greater was the reduction in HbA1c level at all time points as compared to placebo. However, this study had a follow-up of only 3 months [14] . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Although a study in alloxan-induced diabetes in rats compared the efficacy of MNCs and MSCs transplantation and showed that MNCs transplantation was associated with a significant decrease in fasting plasma glucose and greater number of differentiated insulin producing cells as compared to MSCs [15] . No human studies have compared the efficacy and safety of these different autologous bone marrow-derived stem cells in patients with T2DM. Further, while homeostatic model assessment (HOMA) based measures are used to assess the efficacy of therapeutic interventions in patients with diabetes, these tools are recognized to have limitations as longitudinal measures of insulin sensitivity/β-cell function in response to treatment modalities [16] and until now, metabolic studies have not been performed to elucidate the mechanism of reduction in insulin doses with these cell-based therapies.
This prospective, randomized, single-blinded, placebo-controlled study was designed to compare the efficacy and safety of autologous bone marrow-derived mesenchymal stem cell (ABM-MSCs) and mononuclear cells (ABM-MNCs) in patients with T2DM
and examines the alterations in glucose-insulin indices by metabolic studies.
Materials and Methods

Study Design
Seventy patients were screened at out-patient department of the Postgraduate Institute of Medical Education and Research, Chandigarh, India. Informed consent was obtained from the study subjects, Stem Cell Ethics Committee of the institute approved the study and trial was registered at Clinicaltrials.gov (ID number, NCT01759823). The inclusion criteria were: patients of either sex with T2DM, aged between 30 and 60years with duration of diabetes ≥5 years, and failure to achieve HbA1c ≤7.5% (≤58.0mmol/mol), while receiving triple oral anti-diabetic drugs in optimal doses along with insulin (≥0. 
Baseline evaluation
All subjects underwent clinical and biochemical assessment regarding glycemic control and for micro-, and macrovascular complications.
Efficacy Studies
A) Hyperglycemic Clamp Study
Subjects were requested to refrain from vigorous exercise, and anti-diabetic medications were omitted 24h prior to the procedure. Patients reported at 0630h after an overnight fast of 10h for hyperglycemic clamp study [17] . 
B) Glucagon Stimulated C-peptide
The test was performed in fasting state after intravenous (IV) administration of 1mg glucagon, and blood samples were drawn at −15, 0, and 6 min after injection. The homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR), β cell function (HOMA-β) and insulin sensitivity (HOMA-S) were used to assess these indices [21] .
C) Gene expression analysis of Glucose Transporter Type 4 (GLUT-4) and Insulin
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Bioscience). Five milliliters of final wash supernatant was used for sterility testing (aerobic and anaerobic culture, Bactec, BD Bioscience) [11, 24] .
Stem Cells Transplantation
The procedure of stem cell transplantation has been published earlier [11, 24] . Briefly, a 5F catheter (Sim1, Beacon®, USA) was selectively navigated through transfemoral route into the celiac trunk. Within the Sim1 catheter, another caliber catheter (Progreat microcatheter, Terumo, Japan) was selectively advanced into superior pancreatico-duodenal (SPD) artery and cells were injected accordingly unless anatomical variations in vasculature were noted. MSCs were infused at a dose of one million cells per Kg body weight [13] , whereas MNCs at a dose of approximately one billion cells per patients [11, 24] as reported in our previous studies.
Control Group (Group III)
Patients in Group III underwent a sham procedure, which has been described previously [11] . Approximately 20ml of bone marrow was aspirated and after 5h of marrow aspiration, 10 ml of diluted vitamin B complex was injected through transfemoral route into the femoral artery under sterile precautions in the same
ambience. An acellular vehicle was preferred as a control to eliminate the "placebolike effect", if any, of these cell-based therapies
Follow-up
All patients were followed up every 2 weeks for the first month, monthly for the next 3 months, and at three monthly intervals thereafter. Lifestyle modification advice was reinforced during each visit to all the patients. Self-monitoring of blood glucose 
Outcomes
The primary end point was a reduction in insulin requirement by ≥50%, while maintaining HbA1c <7.0% (<53.0mmol/mol) [11] , and the secondary end points included change in weight, HbA1c, metabolic indices including C-peptide and insulin sensitivity as compared to the baseline.
Safety Study
All patients underwent whole body fluorine 18-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET-CT) examination after completion of the study to look for any untoward event.
Statistical Analysis
All the data are expressed as median and interquartile range. Baseline and post treatment data within the groups were compared using Friedman's test with post hoc
Wilcoxon's signed rank test (p value corrected using Bonferroni procedure). Data between the groups were analyzed using the Kruskal Wallis test for continuous variables and Fisher exact tests for categorical variables. Spearman's rank correlation test was used to identify an association between two variables. Generalized linear model was applied for adjustment of baseline variables. The p value <0.05 was considered significant. Statistical analysis was carried out using the SPSS version 22
for window (SPSS Inc., Chicago, USA).
Results
All recruited patients completed the study except one in ABM-MSCs group who was lost to follow-up after 6 months of stem cells transplantation ( Figure 1 ).
ABM-MSCs Group (Group I)
Baseline clinical and biochemical characteristics of the study patients are summarized in the Table 1 . All patients had neuropathy, four had nonproliferative diabetic retinopathy (NPDR), two had proliferative diabetic retinopathy (PDR) and three had microproteinuria. All patients had hypertension, and one had coronary artery disease.
The median volume of the bone marrow harvested for culturing of MSCs was 110.0 (92.5-137.3) ml, which yielded 83.5 (72.0-91.5) X 10 6 MSCs (Table S1 ). More than 90% of MSCs expressed CD73+, CD90+ and CD105+, and were negative for CD34
and CD45 ( Figure S1 ).
In 9 out of 10 patients (90%), MSCs were injected into superior pancreatico- duodenal (SPD) artery, except in one in whom MSCs were injected into the splenic artery due to anatomical malformation. Post-procedure and follow-up study period was uneventful.
A total of six (60%) patients achieved the primary end point (responders) over a mean duration of 5.5(2.8 to 6.0) months, while maintaining HbA1c <7.0% (<53.0 mmol/mol) till the end of the study. There was a 52% reduction in insulin dose in the first 6 months of SCT (p<0.05) followed by a 58% reduction in the next 3 months (p<0.05) and finally by 54% at 12 months (p<0.05) ( Table 2 ). There was a nonsignificant decrease in HbA1c from 6.9% (52.0mmol/mol) to 6.4% (46.0mmol/mol) at 12 months ( Table 2 ). The glucagon stimulated C-peptide modestly increased from 0.7 to 0.8 nmol/L at 12 months, however, there was no significant change in HOMA-IR, HOMA-β and HOMA-S at the end of the study (Table 2) Hyperglycemic clamp, a measure to assess β-cell function, showed that Cpeptide response at baseline and AUC of 1 st phase were insignificant before and after SCT; whereas AUC of 2 nd phase C-peptide response was significantly lower after SCT as compared to baseline (p<0.05) ( Table 2) . Further, generalized linear model analysis showed significant improvement in the insulin sensitivity index (ISI) at the end of the study (p<0.05) ( Table 2 ).
On sub-group analysis, patients in the responder group (n=6) had a significant (p=0.128), respectively.
ABM-MNCs Group (Group II)
Baseline clinical and biochemical characteristics of the study patients are summarized in Table 1 . All patients had neuropathy, two had nonproliferative diabetic retinopathy and four had microproteinuria. Seven patients had hypertension, and one ( Table S1 ) and 1.8(1.4-2.2)X10 7 of these MNCs expressed CD34+.
In 9 out of 10 patients (90%), MNCs were injected into SPD artery, except in one in whom stem cells were injected into the splenic artery due to non-visualization of SPD artery.
After SCT, 6 patients (60%) achieved the primary end point (responders) over a mean duration of 3.5(3.0 to 4.8) months, while maintaining HbA1c <7.0% (<53.0 mmol/mol) till the end of the study period. There was a decrease in the total daily insulin requirement by 51% at 6 months (p<0.05) and maintained at the same dose at 9 (p<0.05) and at 12 months (p<0.05) ( Table 3 ). There was an insignificant increase in HbA1c from 6.7% (50.0mmol/mol) to 7.0% (53.0mmol/mol) at 12 months (Table   3 ). The glucagon stimulated C-peptide significantly increased from 0.7 to 1.1 nmol/L at 12 months (p<0.05) ( Table 3 ). In a sub-group analysis, patients in the responder group (n=6) had insignificant weight loss -0.7Kg (-2.7 to 1.3) (p=0.463) at the achievement of the primary end point and it remained insignificant even at one year -2.4Kg (-3.3 to -0.8) (p=0.173) and did not correlate with reduction in insulin requirement (r=0.551, p=0.257). There was no significant alteration in HOMA-IR, HOMA-β and HOMA-S at the end of the study (Table 3) .
The β-cell function by hyperglycemic clamp study at baseline and AUC of 1 st phase C-peptide response were insignificantly before and after SCT; whereas AUC of 2 nd phase C-peptide response was significantly increased after MNCs transplantation as compared to baseline (p<0.05) (Table 3) . Further, generalized linear model analysis showed a nonsignificant decrease in ISI at the end of the study (p=0.066) ( Table 3) . 
Control Group (Group III)
Baseline clinical and biochemical characteristics of the study patients are summarized in the Table 1 . All patients had neuropathy, five subjects had microproteinuria, two had nonproliferative diabetic retinopathy and one had macroproteinuria. Nine patients had hypertension.
After the "sham procedure", insulin requirement decreased by 10% at the end of the study. However, none of the patients could achieve ≥ 50% reduction in insulin requirement, while maintaining HbA1c <7% ("nonresponders"). The decrease in This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
insulin doses was significant at 6 months (p<0.05), however it could not be sustained at 9 and 12 months (Table 4 ). There was a modest but non-significant weight gain at 9
and 12 months compared to the baseline (Table 5 ). The HbA1c decreased from 6.5%
(47.5mmol/mol) to 6.2% (43.0mmol/mol) without any significant alterations in HOMA-IR, HOMA-β, HOMA-S and stimulated C-peptide at 12 months (Table 4) .
The β-cell function as assessed by hyperglycemic clamp study displayed insignificant alterations in basal, AUC 1 st phase and 2 nd phase C-peptide response and ISI at the end of the study (Table 4) . 
Comparison among the groups
All the groups were comparable at baseline with respect to clinical and biochemical parameters ( Table 1) . On comparing between the groups at 6 and 12 months, the changes in clinical parameters were not statistically significant. The Δ change in insulin dose was significantly more in the ABM-MNCs group compared to the controls at 6 months (p<0.05) as well as at 12 months (p<0.05). However, there was no significant Δ change in insulin dose in ABM-MSCs group as compared to ABMMNCs and control group at 6 and at 12 months. The Δ change in HbA1c was not significantly different between the groups (Table 5) . In hyperglycemic clamp, the increase in Δ change in AUC of 2 nd phase C-peptide response in ABM-MNCs group was significantly higher as compared to ABM-MSCs (p<0.05), while Δ change in ISI significantly improved in ABM-MSCs as compared to ABM-MNCs (p<0.05) and control groups (p<0.05) (Table S2) . On gene expression analysis at 6 months, Δ change in GLUT4 gene expression showed a rising trend but not statistically significant in ABM-MSCs group as compared to others. However, Δ change in IRS1
gene expression was statistically significant in ABM-MSCs as compared to ABMMNCs (p<0.05) group.
Adverse events
Two patients had nausea and vomiting following glucagon administration, which was used for the assessment of β-cell reserve. One patient had local extravasation of blood following the targeted approached through the transfemoral route for the administration of stem cells, which subsided after a week time. None of the patients developed major hypoglycemia, however, average incidence of minor hypoglycemic episodes were 19, 15 and 9 in ABM-MSCs, ABM-MNCs and control groups, respectively, throughout the study period (Table-2 A very few studies have examined the utility of ABM-SCT for the treatment of T2DM in humans. Estrada et al. [12] and Wang et al. [25] showed that combined use of ABM-SCT and hyperbaric oxygen therapy into the dorsal pancreatic artery resulted in reduction in fasting plasma glucose and insulin doses, and an increase in C-peptide levels. However, these studies had certain limitations including lack of placebo arm, heterogeneity in study population at inclusion regarding antidiabetic medication and the majority of patients were lost to follow-up. A recent study showed that the ABM-MNCs treatment could achieve significant reduction in HbA1c with a decrease in oral hypoglycemic drugs and insulin doses compared to intensive insulin therapy [26] . In our previous study, we showed ≥50% reduction in the insulin requirement in 75% of patients with a significant reduction in HbA1c and increase in stimulated C-peptide level after ABM-MNCs therapy, which could be maintained for at least 15 months in almost two third of the patients[24,27]. Another study from our center and the present study also confirm the previous results with the use of ABMMNCs [11] .
There are animal studies showing beneficial effects of MSCs on glucoseinsulin homeostasis. Streptozotocin-induced diabetic rats showed a reduction in blood glucose after allogenic MSCs transplantation and transdifferentiation/fusion of MSCs into insulin-producing cells [28, 29] . Other studies have shown this effect to be short- This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
lived [15] . A recent study demonstrated that MSCs transplantation in early phase of diabetes in a rat model resulted in enhanced insulin secretion, increase in islets number with higher number of insulin positive cells and improved insulin sensitivity, whereas administration in late phase of disease only improved insulin sensitivity by upregulation of GLUT-4 and IRS-1 expression in insulin target tissues [30] . Although there are a few studies that have explored the usefulness of MSCs in patients with
T2DM showing a significant decrease in insulin requirement and increase in Cpeptide [13, 14] , however, these were limited by lack of placebo arm and short duration of follow-up. The present study showed reduction in insulin doses in 60% of patients with the use of ABM-MSCs and these results could be sustained up to one year.
Our study was intentionally designed to enroll patients with HbA1c ≤7.5% (≤ 58.0mmol/mol) in order to mitigate the effect of glucotoxicity on β-cell function and insulin sensitivity, thereby providing an exclusive opportunity to examine the effect of stem cells on these indices. Further, hyperglycemia per se has been shown to have detrimental effect on functionality and survival of stem cells [31] . Although there were no differences in terms of reduction in insulin requirement and achievement of primary end-point between MSCs and MNCs groups, our study provides newer insights into their action. We showed that administration of MSCs was associated with improvement in insulin sensitivity index, thereby resulting in reduction in insulin doses. Furthermore, the adaptive decrease in AUC of 2 nd phase C-peptide response is a surrogate evidence of improvement in insulin sensitivity. In addition, enhancement of IRS-1 expression in patients treated with MSCs suggests that insulin sensitivity may improve through IRS-1-dependent mechanism. On the contrary, the ABM-MNCs administration was associated with augmented C-peptide response on clamp study and this was further supported by significant increase in glucagon-stimulated Cpeptide response. Reduction in insulin doses in the early phases in the control group can be attributed to placebo-like effect, as weight loss of 1.0-3.0 Kg and regular insistence on life-style modification was uniformly observed in all the groups.
However, the decrease in insulin requirement could not be sustained during later half of the study and none of the patients could achieve the primary endpoint. These observations, though a small sample size, suggest that "cocktail" therapy by combining MNCs and MSCs together may be useful in targeting both the defects and could translate into better outcome in terms of reduction in insulin doses and glycemic Approximately 5-10% of weight loss has been shown to be associated with improvement in glycemic profile, lipids and effective control of blood pressure [34] .
There was a significant weight loss (-7.0%) in patients who achieved the primary end point after ABM-MSCs transplantation and it was accompanied with a reduction in insulin doses. This can be attributed to improvement in insulin sensitivity as demonstrated by increase in insulin sensitivity index. However, weight loss did not correlate with decline in the insulin doses as well as with insulin sensitivity index in these patients. Therefore, reduction in insulin doses may be a direct effect of ABMMSCs on insulin sensitivity index rather than mediated by weight loss. On the contrary, patients in the ABM-MNCs group also had a weight loss (-2.9%) but it was insignificant; however, there was a significant reduction in insulin requirement in the responders group which can be attributed to beneficial effects of ABM-MNCs on β-cell function as evidenced by significant improvement in C-peptide response on hyperglycemic clamp. There was also a significant reduction in the insulin requirement for a short duration in the control group without any significant weight loss and this may be attributed to placebo-like effect and initial enthusiasm to adapt life-style modification. Legends- Figure 1 -Schema of the study. Seventy patients were screened, 30 eligible patients were randomized, and were divided into three groups. All patients underwent complete follow-up and analysis excluding one patient lost to follow-up in Group I after 6 months. Figure 1 -Schema of the study. Seventy patients were screened, 30 eligible patients were randomized, and were divided into three groups. All patients underwent complete follow-up and analysis excluding one patient lost to followup in Group I after 6 months. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
